NASDAQ OMX

Minerva Announces Amended Agreement for MIN-202 in Insomnia

Dela

Minerva to gain global strategic control over development of MIN-202 for insomnia

Janssen cash payments to Minerva of up to $70 million, including $30 million upfront

All shares in Minerva held by an affiliate of Janssen (approximately 3.9 million shares representing approximately 10% of outstanding shares) to be repurchased at par value

Minerva Phase 2 development payments totaling $13 million to be waived

WALTHAM, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it has entered into a binding term sheet to amend its co-development and license agreement with Janssen Pharmaceutica NV (Janssen) related to MIN-202 (JNJ 42827922), a selective orexin-2 receptor antagonist, and to repurchase all Minerva shares owned by Johnson & Johnson Innovation - JJDC, Inc. (an affiliate of Janssen).  This amendment and the stock repurchase are conditional upon the closing of the pending acquisition of Actelion Ltd. by affiliates of Janssen and approval by the European Commission.

Under the amended agreement, Minerva will gain global strategic control of the development of MIN-202 to treat insomnia, and Janssen will forego its right to royalties on MIN-202 insomnia sales in Minerva territories.  Minerva will retain its current rights to MIN-202 as adjunctive therapy for major depressive disorder (MDD), which include an exclusive license in the European Union, Switzerland, Liechtenstein, Iceland and Norway, with royalties payable by Minerva to Janssen, and royalties on sales payable by Janssen to Minerva elsewhere worldwide. 

Payments to Minerva by Janssen under this new agreement include an upfront payment of $30 million, $20 million at the start of a Phase 3 insomnia trial for MIN-202 and $20 million when 50% of the patients are enrolled in this trial.  Janssen will waive the remaining payments due from Minerva for Phase 2 development of MIN-202, which total approximately $13 million.  Minerva will assume all financial responsibility for Phase 3 development costs for MIN-202 in insomnia.  All Minerva stock currently owned by Johnson & Johnson Innovation - JJDC, Inc. totaling approximately 3.9 million shares and representing approximately 10% of total Minerva shares outstanding will be repurchased by Minerva at par value of $.0001 per share or approximately $389 in total. 

"We view the new agreement with Janssen as a structure that will ensure a more focused and efficient clinical development of MIN-202 in insomnia by Minerva," said Dr. Remy Luthringer, president and chief executive officer of Minerva.  "We look forward to continuing our collaboration with Janssen while accelerating the clinical advancement of our portfolio.  In addition, the infusion of financial resources under this agreement significantly extends Minerva's financial runway."

Minerva expects that these combined financial resources will support the development of MIN-101, its lead product candidate to treat negative symptoms in schizophrenia, and the development of MIN-202 in insomnia and MDD to the end of 2019.  Within that time frame, Minerva expects to generate data readouts from its planned Phase 3 trial with MIN-101 and three Phase 2b trials with MIN-202 in both indications.  Additional clinical activities planned during that period include a Phase 2 trial with MIN-117 and a Phase 1 trial with MIN-301.

About MIN-202 (JNJ 42827922)

MIN-202 is a selective orexin 2 receptor antagonist under development for the treatment of insomnia and as adjunctive therapy for MDD.  In the brain, the orexin system is involved in the control of several key functions, including metabolism and wakefulness. MIN-202 seeks to inhibit the activity of the neurons that promote wakefulness by selectively blocking the orexin 2 receptor. Rather than making an individual sleepier, blocking the orexin 2 receptor reduces the level of the neurotransmitters that signal the brain to maintain vigilance and wakefulness.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases.  Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."  For more information, please visit www.minervaneurosciences.com

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the approval by the European Commission and subsequent closing of the pending acquisition of Actelion Ltd. by affiliates of Janssen; our ability to negotiate and execute the definitive agreements described above; the timing and results of future clinical milestones with MIN-202 in insomnia and major depressive disorder, including the timing and scope of future clinical trials and results of clinical trials with this compound; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our agreements with Janssen related to MIN-202; our ability to successfully develop and commercialize MIN-101, MIN-202, MIN-117 and MIN-301; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, the inherent uncertainty in approval by the European Commission and subsequent closing of the pending acquisition of Actelion Ltd. by affiliates of Janssen; whether MIN-101, MIN-202, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether the results of future clinical trials of MIN-101, MIN-202, MIN-117 and MIN-301, if any, will be consistent with the results of past clinical trials; whether MIN-101, MIN-202, MIN-117 and MIN-301 will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our co-development agreements; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed with the Securities and Exchange Commission on May 4, 2017.  Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

BIMobject AB: Correction: BIMobject among fastest growing tech companies in EMEA18.12.2017 15:47Pressmeddelande

BIMobject comes in at place 185 in an objective ranking of the 500 fastest growing tech companies in Europe, the Middle East, and Africa. In a corresponding ranking of Swedish companies, BIMobject places 24 th out of 50.  The Deloitte Technology Fast 500(TM) EMEA programme is an objective industry ranking that compares and lists the fastest growing technology companies in Europe, the Middle East, and Africa during the past four years. The 2017 winners were selected based on percentage fiscal-year revenue growth from 2013 to 2016. The regional ranking Sweden Technology Fast 50 lists the fastest growing companies in the Swedish tech industry.  "Our places in the Deloitte rankings are great news proving that our expansion strategy works. The BIMobject Cloud is now the world's leading platform for digital building products. That's the kind of innovation that drives us while we keep working towards growth", says Stef

BIMobject AB: Rättelse: BIMobject bland de snabbast växande techbolagen i EMEA18.12.2017 15:47Pressmeddelande

BIMobject hamnar på plats 185 i objektiv rankning av de 500 snabbast växande techföretagen i Europa, Mellanöstern och Afrika. I motsvarande rankning av svenska företag tilldelas BIMobject plats 24 av 50.  Programmet Deloitte Technology Fast 500(TM) EMEA är en objektiv branschrankning som jämför och listar de snabbast växande techföretagen i Europa, Mellanöstern och Afrika under de senaste fyra åren. Vinnarna för år 2017 valdes ut baserat på procentandelen inkomsttillväxt under räkenskapsåren 2013 till 2016. Den regionala rankningen Sweden Technology Fast 50 listar de snabbast växande företagen inom den svenska techbranschen.  "Våra placeringar i Deloittes rankningar är jätteroliga nyheter som visar att vår strategi för expansion håller. Molnlösningen BIMobject Cloud är nu världens ledande plattform för digitala byggobjekt. Det är sådan innovation vi drivs av samtidigt som vi fortsätter hålla siktet inställt på tillväxt", säger Stefan Larsson, VD och gru

BIMobject AB: BIMobject bland de snabbast växande techbolagen i EMEA18.12.2017 15:18Pressmeddelande

BIMobject hamnar på plats 158 i objektiv rankning av de 500 snabbast växande techföretagen i Europa, Mellanöstern och Afrika. I motsvarande rankning av svenska företag tilldelas BIMobject plats 24 av 50.  Programmet Deloitte Technology Fast 500(TM) EMEA är en objektiv branschrankning som jämför och listar de snabbast växande techföretagen i Europa, Mellanöstern och Afrika under de senaste fyra åren. Vinnarna för år 2017valdes ut baserat på procentandelen inkomsttillväxt under räkenskapsåren 2013 till 2016. Den regionala rankningen Sweden Technology Fast 50 listar de snabbast växande företagen inom den svenska techbranschen.  "Våra placeringar i Deloittes rankningar är jätteroliga nyheter som visar att vår strategi för expansion håller. Molnlösningen BIMobject Cloud är nu världens ledande plattform för digitala byggobjekt. Det är sådan innovation vi drivs av samtidigt som vi fortsätter hålla siktet inställt på tillväxt", säger Stefan Larsson, VD och grun

BIMobject AB: BIMobject among fastest growing tech companies in EMEA18.12.2017 15:18Pressmeddelande

BIMobject comes in at place 158 in an objective ranking of the 500 fastest growing tech companies in Europe, the Middle East, and Africa. In a corresponding ranking of Swedish companies, BIMobject places 24 th out of 50.  The Deloitte Technology Fast 500(TM) EMEA programme is an objective industry ranking that compares and lists the fastest growing technology companies in Europe, the Middle East, and Africa during the past four years. The 2017 winners were selected based on percentage fiscal-year revenue growth from 2013 to 2016. The regional ranking Sweden Technology Fast 50 lists the fastest growing companies in the Swedish tech industry.  "Our places in the Deloitte rankings are great news proving that our expansion strategy works. The BIMobject Cloud is now the world's leading platform for digital building products. That's the kind of innovation that drives us while we keep working towards growth", says Stef

SD-WAN Market Leader, Aryaka, Releases First EMEA Edition of its State of SD-WAN Connectivity Report18.12.2017 15:06Pressmeddelande

Research finds up to 20x cloud and SaaS application performance improvements when connecting via private network-based SD-WANs versus the public Internet LONDON, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, has released its first EMEA Edition of the State of SD-WAN Connectivity report that analyses the performance of SD-WAN deployments over the Internet as compared with those delivered over global private networks. The report highlights specific application response times between various European, Middle East, Asia-Pacific and Americas locations, as well as key factors that impact the performance of cloud and SaaS applications. This research helps IT leaders in Europe, Middle East and Africa (EMEA) to evaluate the best underlying connectivity for their SD-WAN deployments to ensure fast, reliable and consistent performance for all on-premises, cloud and SaaS applications, including voice, video, and data. The report reveals significant dif

Navigators to Acquire Belgian Specialty Insurer18.12.2017 07:30Pressmeddelande

STAMFORD, CT, December 18, 2017 - The Navigators Group, Inc. (NASDAQ:NAVG) today announced that it has entered into a share purchase agreement for the purchase of all of the shares of Assurances Continentales - Continentale Verzekeringen NV ("ASCO") and Bracht, Deckers & Mackelbert NV ("BDM").  ASCO and BDM are both based in Antwerp, Belgium. The proposed acquisition is part of Navigators' strategy of expanding its well-established specialty insurance expertise to more brokers and insureds across Europe. ASCO is a specialty insurance company offering marine and property and casualty insurance. BDM is an insurance underwriting agency that underwrites risk coverage in niche markets on behalf of ASCO and a number of major international insurers. Additionally, as part of the transaction, Navigators will acquire all the shares of Canal Re SA, a Luxembourg reinsurance company that is a wholly-owned subsidiary of ASCO.  The acquisition reinforces Navigators' presence in the European Un

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum